about
Synthesis of some novel organic nitrates and comparative in vitro study of their vasodilator profile.Leishmanicidal activities of novel synthetic furoxan and benzofuroxan derivatives.A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusionOvercoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins.Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells.Doxorubicin-antioxidant co-drugs.Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity.Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein.Design, Synthesis and Characterization of N-oxide-containing Heterocycles with In vivo Sterilizing Antitubercular Activity.(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins.Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance.Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants.Edaravone derivatives containing NO-donor functions.Novel antioxidant agents deriving from molecular combination of Vitamin C and NO-donor moieties.Galactosylated Pro-Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis.NO-donor thiacarbocyanines as multifunctional agents for Alzheimer's disease.Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance.gem-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension.Furazan and furoxan sulfonamides are strong α-carbonic anhydrase inhibitors and potential antiglaucoma agentsSynthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugsNew Nitric Oxide or Hydrogen Sulfide Releasing AspirinsUnsymmetrically substituted furoxans. Part 19. Methyl and phenylfuroxansulfonic acids and related sulfonamidesAmphiphilic NO-Donor AntioxidantsMultitarget drugs: Focus on the NO-donor hybrid drugsNO-Donor COX-2 Inhibitors. New Nitrooxy-Substituted 1,5-Diarylimidazoles Endowed with COX-2 Inhibitory and Vasodilator PropertiesNO-donor melatonin derivatives: synthesis and in vitro pharmacological characterizationNO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator PropertiesSynthesis, chiral HPLC resolution and configuration assignment of 1-phenylglyceryl trinitrate stereomersAceclofenac–Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological EvaluationsNew Tetrahydroisoquinoline Derivatives Overcome Pgp Activity in Brain-Blood Barrier and Glioblastoma Multiforme in VitroNew furoxan derivatives for the treatment of ocular hypertensionCorrection to "Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance"New tetrahydroisoquinoline-based P-glycoprotein modulators: decoration of the biphenyl core gives selective ligandsParacetamol-Galactose Conjugate: A Novel Prodrug for an Old Analgesic DrugNO release regulated by doxorubicin as the green light-harvesting antenna
P50
Q33347110-C7DB3B10-95A2-4CB2-8091-FA8A8782BF7DQ34058373-C162E30D-DBF1-431B-B666-E1B639B975E5Q35193649-822098B2-B212-427D-9C2A-737F53D5DCC9Q35907770-061F67B0-E589-458D-9992-ADBC38453F9DQ38972248-FDF5C977-8338-4E77-9FB1-6CECC623A605Q39105965-BDB1428A-AF54-41BC-8DC3-5DC7D1F31E29Q39514398-2AD36211-C5A1-4101-8473-D773D435CFBAQ39671590-8E1F0B0F-CFC5-4994-965E-6978EF88A361Q41992338-133AF8B9-1CF1-4BD5-8F47-6AC87C9A0696Q43013158-7B3C2C12-175D-4DC1-8F7C-7CE9A970D288Q43838088-FD19E699-CAC2-4105-B136-4F963A59E3B5Q45152465-100F4541-36A7-4C0F-9434-A9D3E61EB479Q46180484-B1FC729C-AE7B-48AE-A77B-DD19E8E56E9EQ46688000-CD03C2EE-EF33-4675-B1B2-64DFDF470A87Q47400103-F6B6F985-3038-439E-94E0-ADFA55100CF5Q48127301-3B50FE49-65DF-47D9-8C64-A080626BE294Q48809877-51001110-AC87-42D6-83A4-450FEFDBF697Q50066089-6DD6BCD4-53CB-4B61-905E-19A8D02D489EQ58863166-47CB0DE5-45F1-4AC4-84EB-27E88C23D2DDQ59545441-0335C86B-B7EA-4803-AE2A-C561142CA48EQ59545502-D345F2DC-58BC-4C7E-B293-A345CB84E7ACQ59545615-58619B65-0626-4ED2-8218-D945D259B768Q59545624-F7E2A60A-D40B-43C8-8459-74376DEBA0BBQ59545630-66307E13-1639-4747-BFE6-23424FF00D9AQ59545648-0BDA53A3-2B45-41BD-BC38-C0ACB44C0F1FQ59545653-D5B226AD-D667-4538-B8E7-4192B3E3F856Q59545662-74FD40DD-2AC2-440E-B663-48323027B917Q59545666-06843E5B-6FD7-455F-A345-8A76958BD07DQ59823945-E2E5A947-7AD7-4C4E-A04A-F69BE7A8D957Q60617024-416489CB-38FD-4EAC-B7B3-84CB709FD966Q63290551-418822D2-4164-449B-8FDA-3765C9261390Q64085350-A4426E6B-1F87-43FD-B7AE-7924AA0D44BEQ90950999-96EC7FCD-AFEE-44C3-BF04-9452136A3276Q92980921-42786121-7BF5-4D0D-9FFC-9289571B2A4FQ95270837-F8C2B865-5B80-438C-B6CE-822851FCCF60
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Konstantin Chegaev
@ast
Konstantin Chegaev
@en
Konstantin Chegaev
@es
Konstantin Chegaev
@nl
type
label
Konstantin Chegaev
@ast
Konstantin Chegaev
@en
Konstantin Chegaev
@es
Konstantin Chegaev
@nl
prefLabel
Konstantin Chegaev
@ast
Konstantin Chegaev
@en
Konstantin Chegaev
@es
Konstantin Chegaev
@nl
P106
P1153
35073634000
P214
1077155042854272402530
P31
P496
0000-0001-9962-1218
P7859
viaf-1077155042854272402530